1 results match your criteria: "Christie Research Center[Affiliation]"
Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer.
Clin Prostate Cancer
September 2005
Medical Oncology Paterson Institute for Cancer Research, Christie Research Center, Manchester, UK.
Background: The safety, tolerability, and pharmacokinetic and preliminary efficacy of PCK3145 were determined in patients with metastatic hormone-refractory prostate cancer.
Patients And Methods: PCK3145 was administered in ascending doses of 5, 20, 40, and 80 mg/m2 3 times per week for 4 weeks to cohorts of 4 patients. Dose escalation was based on dose-limiting toxicity (DLT).